<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047344</url>
  </required_header>
  <id_info>
    <org_study_id>GHNSCLC-2 001</org_study_id>
    <nct_id>NCT02047344</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC</brief_title>
  <official_title>A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Golden Biotechnology Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open label, Phase II study in KRAS-positive and KRAS-negative patients
      with stage IV (including pleural effusion) non squamous NSCLC who have failed two lines of
      anti-cancer therapy. A maximum of 60 evaluable patients with NSCLC will receive
      antroquinonol, of which 30 patients will be KRAS-positive and 30 patients KRAS-negative. An
      evaluable patient will have received at least one dose of antroquinonol and have a valid
      baseline tumor assessment. Enrollment will continue until the target number of evaluable
      patients has been enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Progression free survival rate at 12 weeks, defined as the proportion of patients alive
           and progression free at Week 12. Patients will be progression free if they have no tumor
           assessments of progressive disease (defined according to RECIST guidelines, version 1.1)
           at any point from the start of treatment to Week 12.

        2. Objective response rate (ORR), defined as the proportion of patients whose best overall
           response is either CR or PR according to RECIST version 1.1. The best overall response
           is the best response recorded during the first 12 week treatment cycle.

        3. Disease control rate (DCR), defined as the proportion of patients with a documented CR,
           PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.

        4. Duration of overall tumor response (DR), defined as the interval between the date of the
           first observation of tumor response (CR or PR) and the date of disease progression or
           death.

        5. Progression free survival defined as the time from randomization to objective tumor
           progression by RECIST version 1.1 or death due to any cause, whichever occurs first.

        6. Overall survival (OS) defined as the time from randomization to death from any cause.

        7. Time to progression (TTP) defined as the time from randomization to objective tumor
           progression by RECIST version 1.1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 7, 2018</completion_date>
  <primary_completion_date type="Actual">December 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>8 hours</time_frame>
    <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by non compartmental methods and include: Cmax: peak concentration;Ctrough: trough plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T½: the Time Required for a Quantity to Reduce to Half Its Initial Value</measure>
    <time_frame>8 hours</time_frame>
    <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by T½: terminal half life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to week 48</time_frame>
    <description>the time from the date of first administration of study drug to death from any cause</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Non-small Cell Lung Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Antroquinonol (Hocena)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antroquinonol</intervention_name>
    <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
    <arm_group_label>Antroquinonol (Hocena)</arm_group_label>
    <other_name>Hocena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologically or histologically confirmed non squamous NSCLC Stage IV (including
             pleural effusion).

          -  Radiologically confirmed disease progression following two previous lines of
             anti-cancer therapy, one of which should be a platinum based regimen, OR the patient
             has refused treatment with approved treatment modalities

          -  At least one radiologically measurable target lesion per RECIST version 1.1

          -  Fresh or archival biopsy tissue available to determine tumor mutation status

          -  Written informed consent that is consistent with International Conference on
             Harmonisation Tripartite Guideline on Good Clinical Practice guidelines

          -  Patient or legally acceptable representative has granted written informed consent
             before any study specific procedures (including special Screening tests) are performed

          -  Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2

          -  Hemoglobin ≥ 9.0 g/dL; platelets ≥ 100 x 109/L; absolute neutrophil count ≥ 1.5 x
             109/L without the use of hematopoietic growth factors

          -  Bilirubin and creatinine less than 2 × upper limit of normal (ULN) for the institution

          -  Albumin ≥ 2.5 mg/dL

          -  Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the
             institution

          -  Prothrombin time less than 1.5 × ULN for the institution

          -  Potassium, magnesium and phosphorus within the normal range for the institution
             (supplementation is permissible)

          -  Recovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding
             alopecia

        Exclusion Criteria:

          -  Chemo-, hormone- or immunotherapy, within 4 weeks or within less than four half lives
             of the date of first administration of study drug and/or persistence of toxicities of
             prior anti-cancer therapies which are deemed to be clinically relevant

          -  Radiotherapy within the past 2 weeks prior to date of first administration of study
             drug

          -  Previous treatment with an histone deacetylase inhibitor or an epidermal growth factor
             receptor inhibitor within at least 4 weeks of the date of first administration of
             study drug

          -  Treatment with any drug(s) known to be an inhibitor or inducer of cytochrome P450
             (CYP)2C19, CYP3A4, CYP2C8, and CYP2E1, within 14 days of the date of first
             administration of study drug

          -  Brain metastases, which are symptomatic; patients with treated, brain metastases are
             eligible with stable brain disease for at least 4 weeks without the requirement for
             steroids or anti epileptic therapy

          -  Inability to swallow oral medications or a recent acute gastrointestinal disorder with
             diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for
             Adverse Event (CTCAE) Grade &gt; 2 diarrhea of any etiology at baseline

          -  Other malignancies diagnosed within the past five years (other than curatively treated
             cervical cancer in situ), non melanoma skin cancer, superficial bladder tumors Ta (non
             invasive tumor) and TIS (carcinoma in situ)

          -  Patients with any serious active infection (i.e., requiring an intravenous antibiotic,
             antifungal, or antiviral agent)

          -  Patients with known human immunodeficiency virus, active hepatitis B or active
             hepatitis C

          -  Patients who have any other life threatening illness or organ system dysfunction,
             which in the opinion of the investigator, would either compromise patient safety or
             interfere with the evaluation of the safety of the study drug

          -  Known or suspected substance abuse or alcohol abuse

          -  Pregnancy or breast feeding

          -  History of clinically significant or uncontrolled cardiac disease, including
             congestive heart failure, angina, myocardial infarction, arrhythmia, including New
             York Heart Association functional classification of three
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Cheng, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Golden Biotechnology Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Med Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford health system</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Clinic, Ltd</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Kaohsiung medical center</name>
      <address>
        <city>Kaohsiung</city>
        <zip>88301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospitail</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <results_first_submitted>September 16, 2019</results_first_submitted>
  <results_first_submitted_qc>December 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2019</results_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>need DMC proved</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02047344/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02047344/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Unselected KRAS-positive and KRAS-negative patients with stage IV (including pleural effusion) non squamous NSCLC and radiologically-confirmed disease progression following greater than or equal to two, but less than or equal to four, prior lines of systemic anti cancer therapy.</recruitment_details>
      <pre_assignment_details>Written informed consent was obtained from all patients before initiating screening. The screening period was up to 42 days in duration (Days 42 to 1) for K-Ras testing result, if no history k-Ras result.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>K-Ras Negative</title>
          <description>Fresh or archival biopsy tissue to determine KRAS is not mutant.</description>
        </group>
        <group group_id="P2">
          <title>K- Ras Mutant</title>
          <description>Fresh or archival biopsy tissue to determine KRAS is mutant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16">one patient is not evaluable in process. however, evaluable to safety report.</participants>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>K-Ras Negative</title>
          <description>Fresh or archival biopsy tissue to determine KRAS is not mutant. Patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression.</description>
        </group>
        <group group_id="B2">
          <title>K- Ras Mutant</title>
          <description>Fresh or archival biopsy tissue to determine KRAS is mutant. Patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG performance status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Fully active</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restricted in physically strenuous activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capable of all selfcare more than 50% work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Rate</title>
        <description>Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.</description>
        <time_frame>12 weeks</time_frame>
        <population>Defined as the proportion of patients alive and progression free at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Progression-free Survival Rate/KRAS Negative Group</title>
            <description>200mg TID for treating KRAS negative patients 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Progression-free Survival Rate/KRAS Mutant Group</title>
            <description>200mg TID for treating KRAS negative patients 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Rate</title>
          <description>Tumor response will be assessed at 6 week intervals during the first treatment cycle using the RECIST criteria, version 1.1. Each patient will be assigned one of the following categories: 1) complete response (CR), 2) partial response (PR), 3) stable disease (SD), or 4) progressive disease (PD). Patients who died from any cause or discontinued the study for any reason without a post screening or Week 12 tumor assessment will be considered as failing to respond to treatment.</description>
          <population>Defined as the proportion of patients alive and progression free at Week 12.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by non compartmental methods and include: Cmax: peak concentration;Ctrough: trough plasma concentration.</description>
        <time_frame>8 hours</time_frame>
        <population>There were 22 patients with reported concentration data who were eligible for the PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>Antroquinonol (Hocena)</title>
            <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Antroquinonol Day 28</title>
            <description>continue use Antroquinonol for 28 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by non compartmental methods and include: Cmax: peak concentration;Ctrough: trough plasma concentration.</description>
          <population>There were 22 patients with reported concentration data who were eligible for the PK population.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.87" spread="211.162"/>
                    <measurement group_id="O2" value="393.55" spread="315.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate (DCR)</title>
        <description>the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.</description>
        <time_frame>12 weeks</time_frame>
        <population>26 patients can be run the full analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Non- Prior Chemotherapies</title>
            <description>Patient without any chemotherapy before join Study</description>
          </group>
          <group group_id="O2">
            <title>One Line Failed Prior Chemotherapies</title>
            <description>Patient join with One line failed prior chemotherapies</description>
          </group>
          <group group_id="O3">
            <title>Two Lines Failed Prior Chemotherapies</title>
            <description>Patients join with two lines failed prior chemotherapies</description>
          </group>
          <group group_id="O4">
            <title>More Than Two Lines Failed Prior Chemotherapies</title>
            <description>patient failed more than two line chemotherapies before join.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate (DCR)</title>
          <description>the proportion of patients with a documented CR, PR and SD during the first 12 week treatment cycle according to RECIST version 1.1.</description>
          <population>26 patients can be run the full analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O4" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T½: the Time Required for a Quantity to Reduce to Half Its Initial Value</title>
        <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by T½: terminal half life</description>
        <time_frame>8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antroquinonol (Hocena)</title>
            <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
          </group>
          <group group_id="O2">
            <title>Antroquinonol Day 28</title>
            <description>continue use Antroquinonol for 28 Days</description>
          </group>
        </group_list>
        <measure>
          <title>T½: the Time Required for a Quantity to Reduce to Half Its Initial Value</title>
          <description>PK sampling will be performed on Days 0 and 28 in all patients enrolled in Stage 1.PK endpoints will be derived for intensively sampled PK profiles by T½: terminal half life</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0.5" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="0.5" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Objective Response Rate (ORR)</title>
        <description>Defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.</description>
        <time_frame>12 weeks</time_frame>
        <population>full sey analysis group</population>
        <group_list>
          <group group_id="O1">
            <title>Antroquinonol (Hocena)</title>
            <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
Antroquinonol: patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>Defined as the proportion of patients whose best overall response is either CR or PR according to RECIST version 1.1. The best overall response is the best response recorded during the first 12 week treatment cycle.</description>
          <population>full sey analysis group</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Survival</title>
        <description>the time from the date of first administration of study drug to death from any cause</description>
        <time_frame>up to week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non- Prior Chemotherapies</title>
            <description>Patient without any chemotherapy before join Study</description>
          </group>
          <group group_id="O2">
            <title>One Line Failed Prior Chemotherapies</title>
            <description>Patient join with One line failed prior chemotherapies</description>
          </group>
          <group group_id="O3">
            <title>Two Lines Failed Prior Chemotherapies</title>
            <description>Patients join with two lines failed prior chemotherapies</description>
          </group>
          <group group_id="O4">
            <title>More Than Two Lines Failed Prior Chemotherapies</title>
            <description>patient failed more than two line chemotherapies before join.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>the time from the date of first administration of study drug to death from any cause</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="12.6" upper_limit="88.2"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O4" value="90.9" lower_limit="50.8" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O3" value="28.6" lower_limit="4.1" upper_limit="61.2"/>
                    <measurement group_id="O4" value="39.3" lower_limit="7.3" upper_limit="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs collected for up to 48 weeks of the study from the time the patient signed the informed consent.</time_frame>
      <desc>Patients were followed for AEs from the date of informed consent until resolution or stabilization, alternative treatment for NSCLC was started 6 months after last dose of study drug, or loss to follow-up, whichever occurred first. In the event of serious or study drug-related toxicities, the patient was followed until resolution or stabilization. Safety follow up data was collected by telephone contact every 3 months after the EOS visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Antroquinonol (Hocena)</title>
          <description>patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <description>Atrial fibrillation Cardiac arrest Tachycardia</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Diarrhoea Intestinal obstruction</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Death Disease progression</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Pneumonia Pyelonephritis acute</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Dehydration Hyponatraemia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <description>Malignant neoplasm progression Metastases to central nervous system</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Haematuria Hydronephrosis Ureteric stenosis Urinoma</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Acute respiratory failure Dyspnoea Pulmonary oedema Respiratory distress</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <description>Abdominal pain Abdominal pain upper Diarrhoea Flatulence Nausea Vomiting</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>Catheter site pain Chest pain Fatigue Influenza like illness</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <description>Urine analysis abnormal Weight decreased</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <description>Decreased appetite Dehydration Hypomagnesaemia</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <description>Musculoskeletal pain Pain in extremity</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <description>Malignant neoplasm progression</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <description>Dizziness Headache Neuropathy peripheral</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <description>Insomnia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <description>Haematuria</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <description>Acute respiratory failure Cough Dyspnoea Nasal congestion Pleural effusion Pneumothorax</description>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Cheng</name_or_title>
      <organization>Golden Biotechnology Corp.</organization>
      <phone>+886-2-28086006</phone>
      <email>howard@goldenbiotech.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

